Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bolt Biotherapeutics Inc (NQ: BOLT )

1.128 +0.008 (+0.71%)
Streaming Delayed Price Updated: 10:51 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,918
Open 1.100
Bid (Size) 1.100 (51)
Ask (Size) 1.130 (1)
Prev. Close 1.120
Today's Range 1.100 - 1.130
52wk Range 0.8400 - 2.030
Shares Outstanding 8,709,974
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-2.77%
-2.77%
1 Month
-24.81%
-24.81%
3 Month
+2.54%
+2.54%
6 Month
+13.93%
+13.93%
1 Year
-27.70%
-27.70%

More News

Read More
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
From Pacira BioSciences
Via GlobeNewswire
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Participate in September Investor Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
Via Benzinga
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.